This article is more than 5 years old. Information may no longer be current.
Three-year follow-up shows continued efficacy of latanoprost
Click Here to Manage Email Alerts
FERRARA, Italy — Latanoprost showed long-term efficacy in lowering intraocular pressure in a study here.
Latanoprost 0.005% once daily was effective during 3 years of follow-up in patients with glaucoma for whom beta-blocker therapy was not successful, according to Ciro Costagliola, MD, and colleagues. The researchers performed an unmasked prospective study on 76 patients with glaucoma (145 eyes) treated with latanoprost once daily at bedtime. Latanoprost significantly reduced IOP from a mean of 26.5 mm Hg to 17.4 mm Hg after 36 months of treatment in 48 patients who completed the trial.
Most adverse reactions requiring discontinuation of therapy were allergic reactions. Twenty-eight patients (36.8%) discontinued therapy. In 12 patients, the treatment did not obtain a satisfactory target IOP. In two patients, visual field damage progressed despite IOP reduction. Ten patients experienced side effects including microfollicular conjunctivitis, severe edema of conjunctiva and eyelids, corneal punctate erosion and cystoid macular edema.
The study is published in Graefe's Archive for Clinical and Experimental Ophthalmology.